EP1331930A4 - Verfahren und zusammensetzungen zum regulieren der gedächtnis-konsolidierung - Google Patents

Verfahren und zusammensetzungen zum regulieren der gedächtnis-konsolidierung

Info

Publication number
EP1331930A4
EP1331930A4 EP01924598A EP01924598A EP1331930A4 EP 1331930 A4 EP1331930 A4 EP 1331930A4 EP 01924598 A EP01924598 A EP 01924598A EP 01924598 A EP01924598 A EP 01924598A EP 1331930 A4 EP1331930 A4 EP 1331930A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
memory consolidation
regulating memory
regulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01924598A
Other languages
English (en)
French (fr)
Other versions
EP1331930A2 (de
Inventor
Cristina M Alberini
Mark F Bear
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brown University Research Foundation Inc
Howard Hughes Medical Institute
Original Assignee
Brown University Research Foundation Inc
Howard Hughes Medical Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brown University Research Foundation Inc, Howard Hughes Medical Institute filed Critical Brown University Research Foundation Inc
Publication of EP1331930A2 publication Critical patent/EP1331930A2/de
Publication of EP1331930A4 publication Critical patent/EP1331930A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP01924598A 2000-03-31 2001-04-02 Verfahren und zusammensetzungen zum regulieren der gedächtnis-konsolidierung Withdrawn EP1331930A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19361400P 2000-03-31 2000-03-31
US193614P 2000-03-31
PCT/US2001/010661 WO2001074298A2 (en) 2000-03-31 2001-04-02 Methods and compositions for regulating memory consolidation

Publications (2)

Publication Number Publication Date
EP1331930A2 EP1331930A2 (de) 2003-08-06
EP1331930A4 true EP1331930A4 (de) 2003-08-06

Family

ID=22714335

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01924598A Withdrawn EP1331930A4 (de) 2000-03-31 2001-04-02 Verfahren und zusammensetzungen zum regulieren der gedächtnis-konsolidierung

Country Status (4)

Country Link
EP (1) EP1331930A4 (de)
JP (1) JP2004508288A (de)
AU (1) AU2001251242A1 (de)
WO (1) WO2001074298A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9702518A (es) * 1994-10-07 1998-02-28 Cold Spring Harbor Lab Clonaje y caracterizacion de genes asociados a la memoria a largo plazo.
WO2002052042A2 (en) * 2000-12-22 2002-07-04 Medical Research Council Method for assaying compounds
EP1467207B1 (de) * 2002-01-10 2008-06-04 Takeda Pharmaceutical Company Limited Screening-verfahren für eine prophylaktische und therapeutische Substanz für eine Nierenerkrankung
AUPS255202A0 (en) * 2002-05-27 2002-06-13 Monash University Agents and methods for the treatment of disorders associated with motor neuron degeneration
US20060040338A1 (en) * 2004-08-18 2006-02-23 Odyssey Thera, Inc. Pharmacological profiling of drugs with cell-based assays
US20060094059A1 (en) * 2004-09-22 2006-05-04 Odyssey Thera, Inc. Methods for identifying new drug leads and new therapeutic uses for known drugs

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997046257A1 (en) * 1996-06-03 1997-12-11 The Trustees Of Columbia University In The City Of New York A method for enhancing long-term memory in a subject and uses thereof
WO2001068137A2 (en) * 2000-03-14 2001-09-20 Brown University Research Foundation Compositions for regulating memory consolidation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997046257A1 (en) * 1996-06-03 1997-12-11 The Trustees Of Columbia University In The City Of New York A method for enhancing long-term memory in a subject and uses thereof
WO2001068137A2 (en) * 2000-03-14 2001-09-20 Brown University Research Foundation Compositions for regulating memory consolidation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; February 1999 (1999-02-01), ALEMAN ANDRE ET AL: "Insulin-like growth factor-I and cognitive function in healthy older men.", XP002241280, Database accession no. PREV199900133267 *
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, vol. 84, no. 2, February 1999 (1999-02-01), pages 471 - 475, ISSN: 0021-972X *
RICKARD, N. S. ET AL: "Blockade of metabotropic glutamate receptors prevents long - term memory consolidation", BRAIN RESEARCH BULLETIN (1995), 36(4), 355-9, XP002241279 *

Also Published As

Publication number Publication date
EP1331930A2 (de) 2003-08-06
JP2004508288A (ja) 2004-03-18
AU2001251242A1 (en) 2001-10-15
WO2001074298A3 (en) 2003-05-22
WO2001074298A2 (en) 2001-10-11

Similar Documents

Publication Publication Date Title
AU3946402A (en) Methods and compositions for regulating memory consolidation
AU2001239947A1 (en) Methods and compositions for regulating adipocytes
AU2001285409A1 (en) Memory devices and methods for use therewith
PL351552A1 (en) Gypsum compositions and related methods
IL154217A0 (en) Indazole derivatives as jnk ingibitors and compositions and methods related thereto
EP1176948A4 (de) Anti-nausea zusammensetzungen und methoden
PL364079A1 (en) Arylsulfatase-inhibitors in deodorants and antiperspirants
EP1299068A4 (de) Schwefelhaltige dermatologische zubereitungen und methoden zur verminderung von schlechten gerüchen in dermatologischen zubereitungen
EG23005A (en) Deodorant and/or antiperspirant compositions
AU4163402A (en) Composition and method
GB0020201D0 (en) Cosmetic Composition
IL154422A0 (en) Paroxetine compositions and processes for making the same
AU7311501A (en) Cosmetic composition and method
AU2452502A (en) Compositions for regulating desire for smoking
HU0104832D0 (en) Cosmetic composition and method
AU4215901A (en) Methods and compositions for immunoregulation
IL154267A0 (en) Neuroprotective 2-pyridinamine compositions and related methods
AU2001243635A1 (en) Methods and compositions for regulating memory consolidation
AU2001275409A1 (en) Methods and compositions for controlled polypeptide synthesis
EP1331930A4 (de) Verfahren und zusammensetzungen zum regulieren der gedächtnis-konsolidierung
EP1277459A4 (de) Dauerwellenmittel und verfahren zum dauerwellen mittels dieser
IL145289A0 (en) Method and compositions for regulating memory consolidation
HK1077767A1 (en) Deodorant compositions
AU1182402A (en) Methods and compositions for enhancing angiogenesis
AU2002365136A8 (en) Compositions and methods for controlled release

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20021029

A4 Supplementary search report drawn up and despatched

Effective date: 20030604

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

17Q First examination report despatched

Effective date: 20030922

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040403